March 16, 2023
5 min watch
Nguyen studies consulting for Bayer, Blue Earth Diagnostics, Boston Scientific, Janssen Oncology and Myovant Sciences; and receiving analysis funding from Astellas Pharma, Bayer and Janssen.
On this video, Paul Nguyen, MD, a genitourinary radiation oncologist at Dana-Farber Most cancers Institute, discusses the FORMULA-509 trial he co-presented at ASCO Genitourinary Cancers Symposium.
The research examined sufferers with a rising PSA after radical prostatectomy who had no less than one unfavorable danger issue, and who acquired salvage radiation and 6 months of a gonadotropin-releasing hormone agonist.
“What I feel we will say now could be for a affected person as we speak, utilizing the FORMULA-509 routine is a really engaging various to having to elongate the length of hormone remedy to 24 months,” Nguyen mentioned.
- Nguyen P, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or with out abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). Introduced at: ASCO Genitourinary Cancers Symposium; ; Feb. 16-18, 2023; San Francisco.